Latest period
$530.30M
YoY change
+47.0%
5Y CAGR
+11.0%
Peak year (2025)
$437.60M
Cumulative CapEx
$2.99B
CapEx history chart for Vertex Pharmaceuticals (VRTX) from 1991 to 2025
Latest: $437.60M
CapEx growth chart for Vertex Pharmaceuticals (VRTX) from 1991 to 2025
Latest: +47.0%
CapEx history table for Vertex Pharmaceuticals (VRTX) from 1991 to 2025
| 2025 | $437.60M | +47.0% | +$139.90M | ||
| 2024 | $297.70M | +15.2% | +$39.30M | ||
| 2023 | $258.40M | +26.2% | +$53.70M | ||
| 2022 | $204.70M | -12.9% | −$30.30M | ||
| 2021 | $235.00M | -9.5% | −$24.80M | ||
| 2020 | $259.80M | +244.3% | +$184.35M | ||
| 2019 | $75.45M | -21.0% | −$20.07M | ||
| 2018 | $95.52M | -63.2% | −$163.90M | ||
| 2017 | $259.42M | +358.6% | +$202.86M | ||
| 2016 | $56.56M | +24.9% | +$11.26M | ||
| 2015 | $45.30M | -11.5% | −$5.90M | ||
| 2014 | $51.20M | -0.4% | −$192.00K | ||
| 2013 | $51.39M | -27.8% | −$19.75M | ||
| 2012 | $71.14M | -24.8% | −$23.45M | ||
| 2011 | $94.59M | +148.6% | +$56.54M | ||
| 2010 | $38.05M | +62.0% | +$14.56M | ||
| 2009 | $23.50M | -27.0% | −$8.68M | ||
| 2008 | $32.18M | -0.7% | −$235.00K | ||
| 2007 | $32.41M | -0.0% | −$2.00K | ||
| 2006 | $32.42M | +91.1% | +$15.46M | ||
| 2005 | $16.96M | +35.7% | +$4.46M | ||
| 2004 | $12.49M | -28.0% | −$4.86M | ||
| 2003 | $17.35M | -57.9% | −$23.87M | ||
| 2002 | $41.22M | -23.5% | −$12.68M | ||
| 2001 | $53.90M | +352.4% | +$41.99M | ||
| 2000 | $11.91M | -26.5% | −$4.29M | ||
| 1999 | $16.20M | +105.1% | +$8.30M | ||
| 1998 | $7.90M | +31.7% | +$1.90M | ||
| 1997 | $6.00M | +50.0% | +$2.00M | ||
| 1996 | $4.00M | -25.9% | −$1.40M | ||
| 1995 | $5.40M | +184.2% | +$3.50M | ||
| 1994 | $1.90M | +5.6% | +$100.00K | ||
| 1993 | $1.80M | +20.0% | +$300.00K | ||
| 1992 | $1.50M | +25.0% | +$300.00K | ||
| 1991 | $1.20M | — | — |
- 2025$437.60M+47.0%
- 2024$297.70M+15.2%
- 2023$258.40M+26.2%
- 2022$204.70M-12.9%
- 2021$235.00M-9.5%
- 2020$259.80M+244.3%
- 2019$75.45M-21.0%
- 2018$95.52M-63.2%
- 2017$259.42M+358.6%
- 2016$56.56M+24.9%
- 2015$45.30M-11.5%
- 2014$51.20M-0.4%
- 2013$51.39M-27.8%
- 2012$71.14M-24.8%
- 2011$94.59M+148.6%
- 2010$38.05M+62.0%
- 2009$23.50M-27.0%
- 2008$32.18M-0.7%
- 2007$32.41M-0.0%
- 2006$32.42M+91.1%
- 2005$16.96M+35.7%
- 2004$12.49M-28.0%
- 2003$17.35M-57.9%
- 2002$41.22M-23.5%
- 2001$53.90M+352.4%
- 2000$11.91M-26.5%
- 1999$16.20M+105.1%
- 1998$7.90M+31.7%
- 1997$6.00M+50.0%
- 1996$4.00M-25.9%
- 1995$5.40M+184.2%
- 1994$1.90M+5.6%
- 1993$1.80M+20.0%
- 1992$1.50M+25.0%
- 1991$1.20M—
CapEx values are taken from Vertex Pharmaceuticals's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About CapEx at Vertex Pharmaceuticals (VRTX)
According to Vertex Pharmaceuticals's latest reported financial statements, the company's current CapEx (TTM) is $530.30M. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
In 2025, Vertex Pharmaceuticals (VRTX) CapEx totalled $437.60M – surged 47.0% year-over-year.
Vertex Pharmaceuticals CapEx has grown for 3 consecutive years, with a +11.0% compound annual growth rate over 2020–2025 (5 years).
The highest annual CapEx of $437.60M was reported in 2025. The lowest in the available history was $1.20M in 1991.
Vertex Pharmaceuticals Capital Expenditures by Year
Vertex Pharmaceuticals Capital Expenditures 2025: $437.60M
Vertex Pharmaceuticals posted CapEx of $437.60M in 2025, surged 47.0% from 2024. This figure represents the highest annual value in the available history.
Vertex Pharmaceuticals Capital Expenditures 2024: $297.70M
In 2024, Vertex Pharmaceuticals reported CapEx of $297.70M, grew 15.2% from 2023.
Vertex Pharmaceuticals Capital Expenditures 2023: $258.40M
Vertex Pharmaceuticals CapEx in 2023 was $258.40M, grew 26.2% from 2022.
Vertex Pharmaceuticals Capital Expenditures 2022: $204.70M
2022's CapEx for Vertex Pharmaceuticals came in at $204.70M, declined 12.9% below 2021.
Vertex Pharmaceuticals Capital Expenditures 2021: $235.00M
Vertex Pharmaceuticals CapEx in 2021 was $235.00M.
See more financial history for Vertex Pharmaceuticals (VRTX).
Sector peers by CapEx
Healthcare peers of Vertex Pharmaceuticals (VRTX), ranked by their latest CapEx
| $14.05B | |
| $7.84B | |
| $4.83B | |
| $4.11B | |
| $3.62B | |
| $2.81B | |
| $1.86B | |
| $1.21B |
- $14.05B
- $7.84B
- $4.83B
- $4.11B
- $3.62B
- $2.81B
- $1.86B
- $1.21B
Frequently asked questions
Vertex Pharmaceuticals (VRTX) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation